Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response-Reference-Cited by-同舟云学术

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

Published:2014-09 Issue:10 Volume:15 Page:1137-1146
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

de Azambuja Evandro,Holmes Andrew P,Piccart-Gebhart Martine,Holmes Eileen,Di Cosimo Serena,Swaby Ramona F,Untch Michael,Jackisch Christian,Lang Istvan,Smith Ian,Boyle Frances,Xu Binghe,Barrios Carlos H,Perez Edith A,Azim Hatem A,Kim Sung-Bae,Kuemmel Sherko,Huang Chiun-Sheng,Vuylsteke Peter,Hsieh Ruey-Kuen,Gorbunova Vera,Eniu Alexandru,Dreosti Lydia,Tavartkiladze Natalia,Gelber Richard D,Eidtmann Holger,Baselga José

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

2. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

3. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer;Piccart-Gebhart;N Engl J Med,2005

4. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;N Engl J Med,2005

5. Adjuvant trastuzumab in HER2-positive breast cancer;Slamon;N Engl J Med,2011

Cited by 393 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance;Nature Reviews Clinical Oncology;2024-09-13

2. Inactivation of necroptosis-promoting protein MLKL creates a therapeutic vulnerability in colorectal cancer cells;2024-09-06

3. Advancing Pancreatic Cancer Surgical Treatments and Proposal of New Approaches;Cancers;2024-08-15

4. Role of textural and radiomic analysis parameters in predicting histopathological parameters of the tumor in breast cancer patients;Nuclear Medicine Communications;2024-08-08

5. Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka;Scientific Reports;2024-07-20